| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| HYOSCYAMINE SULFATE | USP Reference standards <11> | USP37–NF32 | 3293 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 2 of USP Hyoscyamine Related Compound A RS: Change (1R,3R,5S)-8-azabicyclo[3.2.1]oct-3-yl(2S)-3-hydroxy-2-phenylpropanoate. to: (1R,3r,5S)-8-Azabicyclo[3.2.1]oct-3-yl(2S)-3-hydroxy-2-phenylpropanoate sulfate (2:1). |
| METHOTREXATE | IMPURITIES/Organic Impurities/Procedure 1: Related Compounds | USP37–NF32 | 3762 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Standard solution A: Change 0.1 μg/mL of USP Methotrexate RS in Solution A, from the Standard stock solution to: 0.1 µg/mL of USP Methotrexate RS in Solution A, from Standard stock solution A |
| PACLITAXEL | Related compounds/Test 2 (for Material Labeled as Produced by a Semisynthetic Process) | USP37–NF32 | 4163 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 6 after table in Chromatographic system: Change the relative standard deviation for replicate injections is not more than 2.0%. to: the relative standard deviation for replicate injections is not more than 2.0% for the paclitaxel peak. |
| PANCURONIUM BROMIDE | ASSAY/Procedure/Chromatographic system | USP37–NF32 | 4176 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Column: Change 4.6-mm × 250-cm; 5-µm packing L1 to: 4.6-mm × 25-cm; 5-µm packing L1 |
| POTASSIUM BITARTRATE | IDENTIFICATION | USP37–NF32 | 4346 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Change C. Identification Tests—General, Tartrate <191> to: C. Identification Tests—General, Tartrate <191>: Meets the requirements AND Delete subsections: Sample solution: 1 in 10 solution Acceptance criteria: Meets the requirements |
| POTASSIUM SODIUM TARTRATE | Identification/C: | USP37–NF32 | 4369 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Change A solution (1 in 10) responds to the tests for Tartrate <191>. to: Responds to the tests for Tartrate <191>. |
| TERAZOSIN TABLETS | PERFORMANCE TESTS/Dissolution <711> | USP37–NF32 | 4874 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 10 of Analysis: Change Mr2 = molecular weight of terazosin hydrochloride dihydrate, 459.92 to: Mr2 = molecular weight of terazosin hydrochloride, 423.89 |
| TETRACAINE OINTMENT | Assay | USP37–NF32 | 4891 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 7 of Procedure: Change (264.37/300.83)(C)(AU / AS) to: (264.36/300.82)(C)(AU / AS) |
| VALSARTAN TABLETS | PERFORMANCE TESTS/Dissolution <711> | USP37–NF32 | 5116 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Medium: Change pH 6.8 phosphate buffer; 1000 mL, degassed to: pH 6.8 phosphate buffer prepared as follows. Dissolve 6.805 g of monobasic potassium phosphate and 0.896 g of sodium hydroxide in and dilute with water to 1000 mL. Adjust with 0.2 M sodium hydroxide or 1 M… Read More |
| ZIPRASIDONE HYDROCHLORIDE | IMPURITIES/Limit of Tetrahydrofuran | USP37–NF32 | 5219 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Standard solution: Change 0.05 mg/mL of USP Ziprasidone Hydrochloride RS in dimethyl sulfoxide to: 0.05 mg/mL of tetrahydrofuran in dimethyl sulfoxide |
| RED CLOVER TABLETS | SPECIFIC TESTS/Microbial Enumeration Tests <2021> | USP37–NF32 | 5526 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 4: Change NLT 103 cfu/g. to: NMT 103 cfu/g. |
| EXTENDED PHENYTOIN SODIUM CAPSULES | IDENTIFICATION/A. Infrared Absorption—General <197> | First Supplement to USP37–NF32 | 6681 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Sample: Change 6 mg/mL of phenytoin sodium in water from a suitable number of Capsules prepared as follows. Nominally transfer 300 mg of the powder into 50 mL of water in a separator. to: 300 mg of phenytoin sodium from the contents of Capsules in 50 mL of water in a… Read More |
| GLYCERYL BEHENATE | ASSAY/Procedure/Chromatographic system | Second Supplement to USP37–NF32 | 7075 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Column: Change 7.0-mm × 60-cm; 5-µm packing L21 [Note—Two 7.0-mm × 30-cm L21 columns to: 7.5-mm × 60-cm; 5-µm 100-Å packing L21 [Note—Two 7.5-mm × 30-cm L21 columns |
| RISPERIDONE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP37–NF32 | 7240 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 2 of USP Risperidone Related Compound G RS: Change 3-[2-[4-(4-Fluoro-2-hydroxybenzoyl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one. C23H28FN3O3 413.49 to: 3-[2-[4-(4-… Read More |
| AMIODARONE HYDROCHLORIDE | ORGANIC IMPURITIES/Procedure 1/Chromatographic system | USP38–NF33 | 2198 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Adsorbent: Change 0.5-mm layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at 254 nm to: Suitable layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at 254 nm |
| ATROPINE SULFATE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP38–NF33 | 2325 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 2 of USP Hyoscyamine Related Compound A RS: Change Norhyoscyamine sulfate; (1R,3r,5S)-8-azabicyclo [3.2.1]oct-3-yl(2S)-3-hydroxy-2-phenylpropanoate.C16H21NO3 275.34 to: Norhyoscyamine sulfate; (1R,3r,5… Read More |
| BUTABARBITAL SODIUM ORAL SOLUTION | ASSAY/Procedure | USP38–NF33 | 2500 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 17 of Analysis: Change CU = nominal concentration of butabarbital sodium in the Sample solution (µg/mL) to: CU = nominal concentration of butabarbital sodium in the Sample solution (mg/mL) |
| BUTABARBITAL SODIUM TABLETS | PERFORMANCE TESTS/Uniformity of Dosage Units <905>/Procedure for content uniformity | USP38–NF33 | 2501 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 18 of Analysis: Change CU = nominal concentration of butabarbital sodium in the Sample solution to: CU = nominal concentration of butabarbital sodium in the Sample solution (mg/mL) |
| CAFFEINE CITRATE INJECTION | ASSAY/Procedure | USP38–NF33 | 2520 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 5 of Analysis: Change Result = (rU/rS) × CS × (Mr1/Mr2) × 100 to: Result = (rU/rS) × C… Read More |
| CAFFEINE CITRATE ORAL SOLUTION | ASSAY/Procedure | USP38–NF33 | 2521 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 5 of Analysis: Change Result = (rU/rS) × CS × (Mr1/Mr2) × 100 to: Result = (rU/rS) × C… Read More |
| CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE TABLETS | ASSAY/Procedure | USP38–NF33 | 2752 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Buffer: Change 0.20 sodium hydroxide to: 0.20 N sodium hydroxide |
| CITRIC ACID, MAGNESIUM OXIDE, AND SODIUM CARBONATE IRRIGATION | ASSAY/Citric Acid | USP38–NF33 | 2844 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 16 of Analysis: Change CU = nominal concentration of citric acid monohydrate in the Assay preparation for citric acid/citrate assay (units/mL) to: CU = nominal concentration of citric acid monohydrate in the Assay… Read More |
| ESCITALOPRAM TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 2 | USP38–NF33 | 3364 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 13 of Analysis: Change Mr2 = molecular weight of escitalopram oxalate, 405.30 to: Mr2 = molecular weight of escitalopram oxalate, 414.43 |
| MESALAMINE RECTAL SUSPENSION | OTHER COMPONENTS/Content of Sodium Benzoate (if present) | USP38–NF33 | 4270 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 5 of Analysis: Change Result = (rU/rS) × CS × (10/W) × 100 to: Result = (rU/rS) × CS × (10/W) |
| PAROXETINE HYDROCHLORIDE | IMPURITIES/Limit of 1-Methyl-4-(p-fluorophenyl)-1,2,3,6-tetrahydropyridine | USP38–NF33 | 4765 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Standard solution: Change 42 mg/mL to: 42 ng/mL |
| PAROXETINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP38–NF33 | 4765 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Lines 4 and 7 of USP Paroxetine System Suitability Mixture A RS: Change hydrochloride (3 S-trans) to: hydrochloride (3S-trans) |
| VALSARTAN AND HYDROCHLOROTHIAZIDE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Revision Bulletin (Official April 01, 2014) | Online | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 2 of USP Valsartan Related Compound B RS: Change (S-N-Butyryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)-valine. to: N-Butyryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine. |
| CIPROFLOXACIN EXTENDED-RELEASE TABLETS | ASSAY/Procedure | Revision Bulletin (Official October 01, 2014) | Online | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 17 of Analysis: Change Mr2 = molecular weight of ciprofloxacin hydrochloride, 367.81 to: Mr2 = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81 |
| CIPROFLOXACIN EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711> | Revision Bulletin (Official October 01, 2014) | Online | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 13 of Analysis in Test 1: Change Mr2 = molecular weight of ciprofloxacin hydrochloride, 367.81 to: Mr2 = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81 AND Line 12 of Analysis in Test… Read More |
| CIPROFLOXACIN EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities | Revision Bulletin (Official October 01, 2014) | Online | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 16 of Analysis: Change Mr2 = molecular weight of ciprofloxacin hydrochloride, 367.81 to: Mr2 = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81 AND Line 14 of the second Calculate statement in Analysis… Read More |
| BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities | Revision Bulletin (Official October 01, 2014) | Online | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Row 4 of Column 1 of Table 16: Change R,S,S,-Thiomorpholine derivativec to: S,R,R,-Thiomorpholine derivativec |
| <659> PACKAGING AND STORAGE REQUIREMENTS | GENERAL DEFINITIONS | USP37–NF32 | 315 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Single-Dose (see also Injections <1>, Containers for Injections): Change A single-unit package for an article intended for parenteral administration. Examples of single-dose containers include prefilled syringes, cartridges, fusion-sealed containers, and closure-… Read More |
| <1788> METHODS FOR THE DETERMINATION OF PARTICULATE MATTER IN INJECTIONS AND OPHTHALMIC SOLUTIONS | LIGHT OBSCURATION PARTICLE COUNT TEST/Instrument Standardization Tests/Particle Counting Accuracy—System Suitability | USP37–NF32 | 1301 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 11 of Method 2—Multichannel Instruments: Change NMT ±10% of stated size. to: NMT ±10% of stated concentration. |
| CEFADROXIL FOR ORAL SUSPENSION | IDENTIFICATION/Thin-Layer Chromatography/Chromatographic system | USP37–NF32 | 2182 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 2 of Developing solvent system: Change (60:40:15) to: (60: 40: 1.5) |
| CEFUROXIME AXETIL FOR ORAL SUSPENSION | ASSAY/Procedure | USP37–NF32 | 2243 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Change Buffer: 23 mg/mL of monobasic ammonium phosphate in water to: Solution A: 23 g/L of monobasic ammonium phosphate in water AND Line 4 of System suitability solution: Change Dilute with Buffer to volume. to: Dilute with Solution A to… Read More |
| DOLASETRON MESYLATE | CHEMICAL INFORMATION | USP37–NF32 | 2693 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 7: Change [115956-13-3]. to: [878143-33-0] Anhydrous [115956-13-3]. |
| FLUDARABINE PHOSPHATE | IMPURITIES/Limit of Sodium | USP37–NF32 | 3003 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Standard solution: Change 1 µg/mL of sodium chloride in water to: 1 µg/mL of sodium in water |
| FLUTAMIDE | ASSAY/Procedure | USP37–NF32 | 3057 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 2 of Sample solution: Change Dissolve the sample in acetonitrile to: Dissolve a previously dried sample in acetonitrile |
| LAMIVUDINE AND ZIDOVUDINE TABLETS | IMPURITIES/Organic Impurities | USP37–NF32 | 3484 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Row 17 of Column 1 of Table 2: Change (the limit includes individual unidentified impurities) to: (the limit includes individual unspecified impurities) |
| MANNITOL INJECTION | Assay | USP37–NF32 | 3653 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Change: Mobile phase, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Mannitol. to: Mobile phase—Use degassed water. Resolution solution—Dissolve sorbitol and USP Mannitol RS in water to obtain a… Read More |
| METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711> | USP37–NF32 | 3732 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Equation in Test 1: Change Result = [(AU/AS) × CS × (V − VS) + (C60 ×VS) + (C180 ×VS) ×100]/L to: Result = [(AU… Read More |
| MINOCYCLINE FOR INJECTION | IMPURITIES | USP37–NF32 | 3843 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 6 of Limit of Epiminocycline: Change [Note—The relative retention times for epiminocycline and minocycline are 0.86 and 1.0, respectively.] to: [Note—The relative retention times for epiminocycline and minocycline are 0.7 and 1.0, respectively.] |
| PETROLATUM | IMPURITIES/Organic Impurities/Procedure: Organic Acids | USP37–NF32 | 4253 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Sample solution: Change 20.0 g of Petrolatum in 100 mL of neutralized alcohol and water (1:2). to: 20.0 g of Petrolatum in 100 mL of a 1 in 2 mixture of neutralized alcohol and water. |
| WHITE PETROLATUM | IMPURITIES/Organic Impurities/Procedure: Organic Acids | USP37–NF32 | 4254 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Sample solution: Change 20.0 g in 100 mL of neutralized alcohol and water (1:2). to: 20.0 g of White Petrolatum in 100 mL of a 1 in 2 mixture of neutralized alcohol and water. |
| SACCHARIN SODIUM | IDENTIFICATION/B. Procedure | USP37–NF32 | 4638 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Analysis: Change To the Sample solution to: To 10 mL of the Sample solution |
| SACCHARIN SODIUM | IMPURITIES/Organic Impurities/Procedure 1: Limit of Toluenesulfonamides | USP37–NF32 | 4638 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 4 of Acceptance criteria: Change of the Internal standard solution to: of the caffeine (internal standard) |
| SULFAMETHOXAZOLE AND TRIMETHOPRIM INJECTION | ASSAY/Procedure | USP37–NF32 | 4784 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 3 of Standard solution: Change in Mobile phase from Sample stock solution to: in Mobile phase from Standard stock solution |
| SULFAMETHOXAZOLE AND TRIMETHOPRIM ORAL SUSPENSION | ASSAY/Procedure | USP37–NF32 | 4785 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 3 of Standard solution: Change in Mobile phase from Sample stock solution to: in Mobile phase from Standard stock solution |
| SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS | ASSAY/Procedure | USP37–NF32 | 4787 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 3 of Standard solution: Change in Mobile phase from Sample stock solution to: in Mobile phase from Standard stock solution |
| ZANAMIVIR | ASSAY/Procedure/Chromatographic system | USP37–NF32 | 5197 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Column: Change 5-μm packing L##1 to: 5-μm packing L82 AND Delete footnote 1 |